Recently, S&P Global, an internationally authoritative sustainability assessment agency, held the launch ceremony for "The Sustainability Yearbook" (China Edition) 2026 in Shanghai. Sino Biopharmaceutical (1177.HK), recognized for its deep commitment and outstanding performance in the field of sustainable development, won three major honors: ranked in the top 5% of the global pharmaceutical industry for the second consecutive year, selected for S&P Global's "The Sustainability Yearbook" (Global Edition) for the second consecutive year, and selected for "The Sustainability Yearbook" (China Edition) for the fourth consecutive year. 

The S&P Global Corporate Sustainability Assessment (CSA) is one of the world's largest annual assessments of corporate sustainability practices, and its results are the primary basis for inclusion in "The Sustainability Yearbook". This year's CSA evaluation involved over 9,200 companies from 59 industries globally, with a total of 848 companies selected for "The Sustainability Yearbook" 2026 (Global Edition)". In the pharmaceutical industry, 269 companies participated globally, with only 23 ultimately being successfully included in the yearbook. 

Receiving these multiple honors signifies high recognition from the world's most authoritative and influential sustainability assessment system for Sino Biopharmaceutical's sustainability practices and performance, fully demonstrating the company's industry-leading ESG governance level and core competitiveness in sustainable development. 

Sino Biopharmaceutical has always upheld the development philosophy of "Health Technology, Warming More Lives", deeply integrating sustainable development into its corporate strategic layout. In 2025, with the full implementation of its first three-year ESG plan, Sino Biopharmaceutical launched the "2025-2027 New Three-Year ESG Plan". This plan focuses on the core development directions of "strengthening innovative R&D, expanding pharmaceutical accessibility, deepening green development, and perfecting the responsibility system", promoting the transformation of ESG management from "systematic construction" to "high-quality leadership". In the future, Sino Biopharmaceutical will adhere to higher standards of sustainable development practices to create long-term value for all stakeholders and contribute to the high-quality, sustainable development of the global pharmaceutical and healthcare industry.